Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Transaminase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN106399418B reveals a transaminase route for moxifloxacin intermediates. Achieve >99% ee and reduced costs with our scalable biocatalytic manufacturing solutions.
Patent CN115466756A discloses novel immobilized transaminases for sitagliptin production. Achieve high conversion, stability, and cost reduction in pharmaceutical manufacturing.
Patent CN117467733B reveals immobilized transaminase process for Sitagliptin. Achieve high optical purity and cost reduction in API manufacturing with scalable biocatalysis.
Patent CN109576238A reveals efficient transaminase route for chiral beta-amino alcohols. Enables cost reduction and high-purity supply for pharmaceutical intermediates manufacturing.
Patent CN119698468A details engineered transaminases for niraparib synthesis, offering high stereoselectivity and scalable biocatalytic solutions for pharmaceutical supply chains.
Patent CN115975969B reveals advanced transaminase mutants for Sitagliptin. Achieve high conversion and stereoselectivity for reliable pharmaceutical intermediate supply chains.
Patent CN106801043B reveals high-efficiency enzymatic synthesis for Sitagliptin intermediates, offering superior purity and scalable supply chain solutions for global pharmaceutical manufacturing.
Patent CN106995807B reveals high-activity transaminase for Sitagliptin. Enables cost reduction in pharmaceutical intermediates manufacturing with superior enantioselectivity.
Patent CN112553285B reveals a novel omega-transaminase method for L-glufosinate-ammonium. Achieve high purity and cost reduction in agrochemical manufacturing with scalable biocatalysis.
Patent CN116064449A discloses stable transaminase mutants for bulky chiral amines. Enables green synthesis, cost reduction, and reliable supply for pharmaceutical intermediates.
Patent CN114075557B reveals enzymatic synthesis for high-purity Larotrectinib intermediate. Achieve cost reduction and scalable supply chain reliability.
Patent CN120718880A reveals high-efficiency biocatalysis for chiral amines. Achieve superior purity and reduced manufacturing costs with scalable enzyme technology.
Patent CN113789310B reveals high-yield transaminase route for moxifloxacin intermediates, eliminating DMSO for cost-effective and scalable API manufacturing.
Patent CN119530189A reveals green enzymatic route for cyclohexylamine. Offers high selectivity and reduced environmental impact for pharmaceutical intermediate supply chains.
Novel recombinant (R)-ω-transaminase mutant enables high-yield sitagliptin production with superior stereoselectivity and enzyme activity for pharmaceutical supply chains.
Patent CN109609477B details a novel alpha-transaminase mutant enabling 100% conversion in L-glufosinate-ammonium synthesis, offering significant cost reduction and supply chain reliability for agrochemical manufacturers.
Patent CN115975969A discloses high-efficiency transaminase mutants for Sitagliptin synthesis, offering superior conversion rates and stability for cost reduction in API manufacturing.
Patent CN116004562A reveals a quadruple transaminase mutant boosting D-4,4'-biphenylalanine production efficiency by 30-fold, offering a scalable, high-purity solution for LCZ696 intermediates.
Patent CN104131048A reveals high-yield biological synthesis for chiral intermediates. Achieve superior purity and cost efficiency in pharmaceutical manufacturing supply chains.
Patent CN113881720B reveals enzymatic synthesis for high-purity intermediates. Achieve cost reduction and supply chain reliability with scalable biocatalysis.